NDAORALSOLUTIONPriority Review
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Clinical Trials (1)
Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia
Started Feb 2021
Loss of Exclusivity
LOE Date
Apr 16, 2038
147 months away
Patent Expiry
Apr 16, 2038
Company
R-Pharm US
NJ - Princeton